videoSlug

VideoSlug_VideoQuery

slug

VideoPageContentQuery

content

videos

query VideoSlug_VideoQuery(
  $videoSlug: String!
) {
  ...VideoPageContentQuery_1X4EH4
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment LatestVideos_Videos on Query {
  videos(first: 5, upcoming: false, order: {field: liveTime, direction: DESC}) {
    edges {
      node {
        id
        title
        lang
        pageUrl
        liveTime
        isLive
        companies {
          name
          squareLogoUrl
          id
        }
      }
    }
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment VideoPageContentQuery_1X4EH4 on Query {
  content(slug: $videoSlug, type: [VIDEO, WEBCAST]) {
    __typename
    id
    title
    slug
    lang
    htmlBody
    isPremium
    companies {
      viewerIsFollowing
      id
      name
      pageUrl
      defaultInstrument {
        id
        isin
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    createdAt
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    ... on Video {
      imgUrl
      videoEmbedUrl(location: "inderes")
      audioEmbedUrl
      registrationInfoHtml
      registrationUrl
      liveTime
    }
    ... on Webcast {
      imgUrl
      videoEmbedUrl(location: "inderes")
      registrationInfoHtml
      registrationUrl
      liveTime
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
  }
  ...LatestVideos_Videos
}


type

__typename

title

lang

htmlBody

isPremium

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

first

order

upcoming

edges

Embla Medical

Embla Medical will release its Q1 2025 interim report on the 29 April 2025. The same day at 10.30 AM, the company’s management will present the results and answer questions in an online live event. We expect a presentation of the financial results and an update on the recent business and regulatory developments.

You can already now sign up for the event and send in your questions. You don&#x2019;t have to participate live to submit questions for the event. Embla Medical will release its Q1 2025 interim report on 29 April 2025. The same day at 10.30 AM, the company&#x2019;s management will present the results and answer questions in an online live event. We expect a presentation of the financial results and an update on the recent business and regulatory developments. In 2025, the company expects organic growth between 5-8%, with 6% realized in 2024. Growth is primarily expected to be driven by new product launches in the Bionic series, impacts from the expansion of the US Medicare Coverage, and leverage of the Fior &amp; Gentz acquisition with the roll-out of their offerings to new markets. The EBITDA margin with guidance of 20-21% vs. 20% realized in 2024 is expected to improve (mid-range). Besides topline growth, margins are expected to be positively impacted by positive product mix effects from increased sales in high-end solutions, as well as continued efficiency gains in manufacturing. Besides the financial Q1 25 results and how they track vs. the full year guidance, focus could be on comments on the potential of tariffs, as the 2025 guidance doesn&#x2019;t include any potential negative effects from changes here. Embla Medical is a leading global provider of innovative mobility solutions in the medical technology space. Embla Medical improves people&#x2019;s mobility through the delivery of Prosthetics &amp; Neuro Orthotics, Bracing &amp; Supports, and Patient Care. Dislcaimer: HC Andersen Capital receives payment from Embla Medical for a Corporate Visibility/Digital IR subscription agreement. /Michael Friis, 11.27 AM, 31-03-2025.

Embla Medical – Presentation of Q1 2025 interim report

Recent videos